CRVS - Company ID 0001626971
The table below shows Corvus Pharmaceuticals, Inc.'s balance sheet by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q2 2026 | Q1 2026 | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $18.91M | $40.10M | $2.87M | $14.69M | $5.00M | $4.68M |
| Short-term investments | - | - | - | - | - | - |
| Receivables | $6.00K | $43.00K | $32.00K | $86.00K | $79.00K | $70.00K |
| Inventory | - | - | - | - | - | - |
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| Total current assets |
| $220.97M |
| $239.95M |
| $66.94M |
| $75.78M |
| $45.49M |
| $42.92M |
| Property, plant & equipment | $830.00K | $282.00K | $221.00K | $249.00K | $165.00K | $171.00K |
| Goodwill | - | - | - | - | - | - |
| Total assets | $239.27M | $253.19M | $80.47M | $89.46M | $59.44M | $58.81M |
| Accounts payable | $4.05M | $4.70M | $1.97M | $3.14M | $1.31M | $1.87M |
| Total current liabilities | $13.67M | $12.11M | $8.07M | $8.51M | $9.28M | $46.41M |
| Long-term debt | - | - | - | - | - | - |
| Total liabilities | $13.95M | $12.52M | $8.71M | $9.23M | $10.11M | $46.41M |
| Retained earnings | -$443.94M | -$425.99M | -$399.97M | -$389.81M | -$381.82M | -$384.90M |
| Total equity | $225.33M | $240.68M | $71.77M | $80.23M | $49.33M | $12.41M |